- Which of the following investigations is required to establish a definitive diagnosis?
Answer: Bone marrow aspiration and biopsy
The patient's presentation with pancytopenia (anemia, thrombocytopenia, and neutropenia) and a low reticulocyte count (indicating a hypoproliferative state) is highly suspicious for aplastic anemia. While other conditions can cause pancytopenia, the most definitive diagnostic test to confirm aplastic anemia is a bone marrow aspiration and biopsy. This will show a markedly hypocellular or 'empty' marrow, with fat replacing hematopoietic cells. Vitamin levels should be checked, but they are unlikely to explain the full picture. Flow cytometry is used for PNH or leukemia. An ultrasound might show splenomegaly but is not diagnostic for the primary marrow failure.
- Which of the following is the most appropriate initial treatment for this patient's condition?
Answer: Oral ferrous sulfate
This patient presents with classic signs and symptoms of iron deficiency anemia (fatigue, exertional dyspnea, pica, koilonychia) secondary to menorrhagia, confirmed by microcytic anemia on lab testing. The most appropriate initial treatment for uncomplicated iron deficiency anemia in a hemodynamically stable patient is oral iron replacement, such as ferrous sulfate. Blood transfusion is reserved for hemodynamically unstable patients or those with severe symptoms (e.g., angina). IV iron is typically used for patients who cannot tolerate or absorb oral iron, or have ongoing blood loss that outpaces oral replacement. Erythropoietin is used for anemia of chronic kidney disease or chemotherapy-induced anemia.
- A 55-year-old woman developed fatigue after 6 months of hydroxyurea therapy for essential thrombocythemia. Labs: Hb 5.9 g/dL, MCV 118 fL, leukocytes 3,400/µL, platelets 52,000/µL. Reticulocytes are low. Serum iron and B12 are normal. Examination of bone marrow shows many megaloblastoid erythroid precursors containing iron-laden mitochondria forming perinuclear rings. Which agent could be added to improve her cytopenias?
Answer: Pyridoxine (vitamin B6) to enhance heme synthesis in sideroblastic precursors
When you encounter a patient with cytopenias after chemotherapy showing megaloblastoid changes and iron-laden mitochondria forming perinuclear rings, you're looking at acquired sideroblastic anemia. This condition occurs when iron accumulates in mitochondria due to impaired heme synthesis, creating the characteristic "ringed sideroblasts" on bone marrow examination.
Hydroxyurea, while effective for essential thrombocythemia, can interfere with folate metabolism and heme synthesis pathways. The key clue here is that B12 and serum iron are normal, but you're seeing megaloblastic features with sideroblastic changes - this points to a problem in the heme synthesis pathway rather than classical B12/folate deficiency.
Pyridoxine (vitamin B6) is the correct treatment because it serves as a cofactor for δ-aminolevulinic acid synthase, the first and rate-limiting enzyme in heme synthesis. Supplementing with pyridoxine can overcome the metabolic block and improve heme production, thereby reducing the cytopenia.
Option B (deferoxamine) treats iron overload but won't address the underlying enzymatic defect causing iron to accumulate in mitochondria. Option C (prednisone) would be appropriate for autoimmune cytopenias, but this patient has a drug-induced metabolic problem, not immune destruction. Option D (filgrastim) only stimulates white cell production and ignores the underlying heme synthesis defect affecting all cell lines.
Remember: acquired sideroblastic anemia from chemotherapy often responds to pyridoxine supplementation, even when B6 levels appear normal, because the drugs create a functional deficiency at the enzymatic level.
- A 53-year-old man presents with exertional dyspnea. Complete blood count: Hb 6.8 g/dL, MCV 66 fL, leukocytes 7,000/µL, platelets 280,000/µL. Iron studies: serum iron 210 µg/dL (60-170), transferrin saturation 85%, ferritin 1,100 ng/mL. Hemoglobin electrophoresis: HbA2 6.2% (normal 1.5-3.5), HbF 3%. Which of the following is the most appropriate long-term management to prevent disease complications?
Answer: Chelation therapy with deferasirox to prevent secondary hemosiderosis from transfusional iron
When you encounter microcytic anemia with elevated iron studies and increased HbA2, you're dealing with beta-thalassemia. This patient's presentation—microcytic anemia (MCV 66 fL), elevated HbA2 (6.2%), and iron overload (high serum iron, transferrin saturation 85%, ferritin 1,100)—points to beta-thalassemia intermedia or major.
The correct answer is C because beta-thalassemia patients develop iron overload through two mechanisms: ineffective erythropoiesis (which increases iron absorption) and repeated transfusions. This iron accumulates in organs (heart, liver, endocrine glands), causing life-threatening complications like cardiomyopathy and cirrhosis. Chelation therapy with deferasirox prevents this secondary hemosiderosis.
A is incorrect because phlebotomy would worsen the anemia in someone who's already severely anemic (Hb 6.8 g/dL). While it might reduce iron, it doesn't address the underlying ineffective erythropoiesis.
B describes supportive care rather than preventive management. While transfusions may be needed acutely, they actually contribute to iron overload long-term without addressing the complications.
D is completely wrong—giving more iron to someone with iron overload would be harmful. Erythropoietin won't correct the fundamental hemoglobin synthesis defect in thalassemia.
Study tip: When you see microcytic anemia with paradoxically high iron studies, think thalassemia. The key insight is that iron overload in thalassemia comes from both increased absorption and transfusions, making chelation the cornerstone of preventing long-term complications.
- A 22-year-old woman presents with acute onset pallor and fatigue three weeks after starting chloramphenicol for typhoid fever obtained overseas. CBC shows Hb 5.8 g/dL, MCV 92 fL, leukocytes 1,100/µL, platelets 15,000/µL. Bone marrow biopsy reveals hypocellularity with fatty infiltration. What is the most appropriate initial therapy?
Answer: Discontinue drug and initiate combination immunosuppression with antithymocyte globulin plus cyclosporine
When you encounter severe pancytopenia after drug exposure, think aplastic anemia. This patient's presentation—pancytopenia (low Hb, WBC, and platelets) with hypocellular bone marrow containing fatty infiltration—is classic for drug-induced aplastic anemia, particularly from chloramphenicol, which is notorious for this potentially fatal complication.
The correct approach is option B: discontinue the offending drug immediately and start combination immunosuppression with antithymocyte globulin (ATG) plus cyclosporine. Aplastic anemia results from immune-mediated destruction of hematopoietic stem cells, making immunosuppression the cornerstone of treatment. ATG targets T-lymphocytes that attack bone marrow, while cyclosporine provides sustained immunosuppression. This combination has proven efficacy in restoring marrow function.
Option A (IVIG and plasmapheresis) treats antibody-mediated disorders like thrombotic thrombocytopenic purpura, not aplastic anemia where the pathophysiology involves cellular immunity. Option C (myeloablative chemotherapy with autologous rescue) is used for hematologic malignancies, not aplastic anemia—plus this patient's marrow is already destroyed, making autologous rescue impossible. Option D (erythropoietin and G-CSF) won't work because there are virtually no functioning stem cells to stimulate in severe aplastic anemia.
Remember this pattern: drug-induced aplastic anemia requires immediate drug discontinuation plus immunosuppression. Chloramphenicol, sulfonamides, and chemotherapy agents are classic culprits. Always consider bone marrow transplant for young patients with severe disease and available matched donors.
- What is the most likely diagnosis?
Answer: Vitamin B12 deficiency
This patient's presentation of macrocytic anemia (MCV 115) with characteristic peripheral smear findings (hypersegmented neutrophils) and prominent neurologic symptoms (paresthesias, gait instability, memory changes) is classic for vitamin B12 (cobalamin) deficiency. Her history of partial gastrectomy is a significant risk factor, as it can lead to the loss of intrinsic factor-producing parietal cells, causing malabsorption of B12. Folate deficiency causes a similar megaloblastic anemia but does not cause the neurologic deficits seen here. Myelodysplastic syndrome can cause macrocytic anemia but is less likely to present with these specific neurologic findings. Anemia of chronic disease is typically normocytic or mildly microcytic.
- A 25-year-old African American man develops dark urine and jaundice two days after receiving trimethoprim-sulfamethoxazole for prostatitis. Vitals are stable. Labs: Hb 7.8 g/dL (baseline 14), MCV 90 fL, reticulocytes 15%, LDH 680 U/L (100-220), haptoglobin undetectable, total bilirubin 5 mg/dL (mostly indirect). Peripheral smear reveals bite cells. Which additional test is most likely to confirm the underlying diagnosis once the episode resolves?
Answer: Quantitative glucose-6-phosphate dehydrogenase level repeated after recovery
This question tests your ability to recognize drug-induced hemolytic anemia and understand the timing of diagnostic testing for enzyme deficiencies.
The clinical picture screams hemolytic anemia: dramatic hemoglobin drop, elevated reticulocytes and LDH, undetectable haptoglobin, and indirect hyperbilirubinemia. The key clues are the African American ethnicity, trimethoprim-sulfamethoxazole trigger, and bite cells on smear. Bite cells are pathognomonic for oxidative hemolysis, which occurs when red cells can't handle oxidative stress due to glucose-6-phosphate dehydrogenase (G6PD) deficiency.
G6PD deficiency is X-linked and common in African Americans. During hemolytic episodes, G6PD-deficient cells are preferentially destroyed, leaving behind younger cells with higher enzyme levels, which can falsely normalize G6PD levels. Therefore, you must wait until after recovery to get an accurate measurement, making choice D correct.
Choice A is wrong because pyruvate kinase deficiency causes chronic hemolysis, not episodic oxidative crises triggered by specific drugs. Choice B tests for hereditary spherocytosis, which presents with spherocytes, not bite cells, and isn't typically drug-induced. Choice C evaluates for paroxysmal nocturnal hemoglobinuria (PNH), but PNH doesn't cause bite cells and isn't associated with sulfa drugs.
Remember this key principle: When you suspect G6PD deficiency during an acute hemolytic episode, always retest enzyme levels after the crisis resolves. Testing during acute hemolysis often gives falsely normal results due to selective destruction of deficient cells.
- A 28-year-old woman at 30 weeks' gestation is found to have Hb 8.1 g/dL and MCV 71 fL. Ferritin is 8 ng/mL, serum iron is low, and total iron-binding capacity is high. She was intolerant of multiple oral iron formulations because of severe nausea. What is the best next step to correct her anemia before delivery?
Answer: Schedule intravenous low-molecular-weight iron sucrose infusions over two sessions
When you encounter iron deficiency anemia in pregnancy with oral iron intolerance, you need to consider the severity, gestational age, and safest parenteral iron options. This patient has moderate iron deficiency anemia (Hb 8.1 g/dL, MCV 71 fL, low ferritin) at 30 weeks with 10 weeks until delivery.
Answer C is correct because intravenous iron sucrose is the safest and most effective parenteral iron for pregnant women who cannot tolerate oral iron. Low-molecular-weight iron sucrose has an excellent safety profile in pregnancy, doesn't require test dosing, and can effectively replenish iron stores over 1-2 infusion sessions. With 10 weeks remaining, there's adequate time for the iron to stimulate erythropoiesis and raise hemoglobin levels.
Answer A is wrong because iron dextran, while effective, carries a higher risk of serious allergic reactions including anaphylaxis, making iron sucrose the preferred parenteral option in pregnancy.
Answer B is incorrect because vitamin C supplementation alone won't address the fundamental problem - she cannot tolerate any oral iron formulations due to severe nausea, so enhancing absorption won't help.
Answer D is wrong because her hemoglobin of 8.1 g/dL, while low, doesn't meet the threshold for urgent transfusion (typically <7 g/dL in stable patients). Transfusion carries unnecessary risks including infection, alloimmunization, and iron overload.
Remember: For pregnant patients with iron deficiency anemia who can't tolerate oral iron, IV iron sucrose is first-line therapy. Reserve transfusions for severe anemia (<7 g/dL) or hemodynamic instability.
- A 60-year-old woman with a history of heavy ibuprofen use presents with melena and dizziness. She receives 2 liters of crystalloid and stabilizes. Vitals: BP 105/60 mmHg, HR 90/min. Hb 6.5 g/dL, MCV 79 fL. Cross-match reveals O-positive type. What is the most appropriate transfusion strategy?
Answer: Administer 1 unit of packed red blood cells and reassess hemoglobin after each unit, targeting 7-8 g/dL
When you encounter a patient with GI bleeding and significant anemia, you need to balance the benefits of transfusion against potential risks while following evidence-based thresholds.
This patient has upper GI bleeding (melena) likely from NSAID-induced peptic ulcer disease, resulting in iron deficiency anemia (low MCV). Although her hemoglobin is critically low at 6.5 g/dL, she's hemodynamically stable after fluid resuscitation, making this a controlled bleeding scenario.
The correct approach (D) follows current transfusion guidelines: give one unit at a time and reassess, targeting hemoglobin of 7-8 g/dL. This restrictive strategy reduces transfusion-related complications while providing adequate oxygen-carrying capacity for most patients without active cardiac ischemia.
Option A represents the older, more liberal transfusion strategy targeting hemoglobin >8 g/dL, which studies have shown increases complications without improving outcomes in hemodynamically stable patients. The fear of "myocardial ischemia" at these levels is overstated in stable patients.
Option B sets the threshold dangerously low at 5 g/dL. While the patient is stable now, waiting until hemoglobin drops further unnecessarily risks cardiovascular compromise and doesn't address her current symptomatic anemia.
Option C suggests iron infusion instead of transfusion, which is inappropriate for acute, severe anemia. Iron therapy takes weeks to months to increase hemoglobin and won't address her immediate needs.
Key takeaway: For stable patients with GI bleeding, use restrictive transfusion thresholds (7-8 g/dL), transfuse one unit at a time, and reassess. This evidence-based approach optimizes outcomes while minimizing transfusion risks.
- A 44-year-old man with ulcerative colitis presents with jaundice and dark urine 4 days after receiving piperacillin-tazobactam for cellulitis. Exam: scleral icterus, no splenomegaly. Labs: Hb 8.9 g/dL, MCV 92 fL, reticulocytes 12%, indirect bilirubin 4.2 mg/dL, LDH 520 U/L, haptoglobin low. Direct antiglobulin (Coombs) test is strongly positive for IgG and complement. What is the best initial treatment?
Answer: High-dose intravenous methylprednisolone to dampen autoantibody production
When you encounter a patient with acute hemolysis and a positive direct antiglobulin test, you're dealing with autoimmune hemolytic anemia (AIHA). The key clinical clues here are the timing (4 days post-antibiotic), elevated indirect bilirubin, low haptoglobin, high reticulocyte count, and strongly positive Coombs test for both IgG and complement—all pointing to drug-induced warm AIHA.
High-dose intravenous methylprednisolone (A) is correct because corticosteroids are the first-line treatment for warm AIHA. They work by suppressing autoantibody production and reducing macrophage-mediated hemolysis in the spleen. The "high-dose IV" specification is important because severe hemolysis requires aggressive immunosuppression.
Option B is incomplete—while discontinuing the offending antibiotic is necessary, folic acid alone won't address the underlying autoimmune process causing ongoing hemolysis. Option C (exchange transfusion) is reserved for life-threatening cases when the hemoglobin is critically low or hemolysis is refractory to steroids. This patient's hemoglobin of 8.9 g/dL, while low, doesn't meet criteria for emergency intervention. Option D (IVIG) is typically used for cold agglutinin disease or as second-line therapy when steroids fail.
Remember that drug-induced AIHA often presents within days of starting certain antibiotics (especially penicillins, cephalosporins). Always look for the temporal relationship between drug exposure and hemolysis onset. The treatment hierarchy is: discontinue the drug + high-dose steroids first, then escalate to IVIG, rituximab, or splenectomy if refractory.
- A 70-year-old man presents with easy bruising and recurrent infections. CBC shows Hb 10.0 g/dL, MCV 105 fL, leukocytes 2,200/µL, platelets 75,000/µL. Reticulocyte count is low. Peripheral smear demonstrates hypogranular neutrophils with bilobed nuclei (pseudo-Pelger-Huët cells) and occasional ring sideroblasts. Which of the following best describes the underlying disorder?
Answer: Clonal stem cell disease leading to ineffective hematopoiesis and risk of acute myeloid leukemia
When you encounter pancytopenia with morphologic abnormalities in an elderly patient, think systematically about the underlying pathophysiology affecting the bone marrow.
This case demonstrates classic features of myelodysplastic syndrome (MDS). The key diagnostic clues are the combination of cytopenias (anemia, leukopenia, thrombocytopenia) with low reticulocyte count, indicating bone marrow failure rather than peripheral destruction. Most importantly, the peripheral smear shows dysplastic changes: pseudo-Pelger-Huët cells (neutrophils with abnormally bilobed nuclei) and ring sideroblasts. These morphologic abnormalities are hallmarks of dysplasia—abnormal cellular development despite adequate bone marrow cellularity.
Choice A correctly identifies MDS as a clonal stem cell disorder causing ineffective hematopoiesis (cells are produced but defective) with significant risk of transformation to acute myeloid leukemia (15-20% lifetime risk).
Choice B describes aplastic anemia, which would present with pancytopenia but without dysplastic changes and would show hypocellular bone marrow, not the cellular abnormalities described here.
Choice C suggests megaloblastic anemia from B12 deficiency. While this can cause macrocytic anemia and pancytopenia, it wouldn't produce pseudo-Pelger-Huët cells or ring sideroblasts—these are specific markers of clonal stem cell disease.
Choice D describes primary myelofibrosis, which typically presents with teardrop cells and extramedullary hematopoiesis, not the specific dysplastic features shown.
Remember: Dysplastic cellular morphology in the setting of cytopenias strongly suggests MDS. The combination of quantitative deficiency with qualitative abnormalities distinguishes this from other causes of bone marrow failure.
- Which of the following findings on hemoglobin electrophoresis is most consistent with the suspected diagnosis?
Answer: Increased Hemoglobin A2
The patient's clinical picture of asymptomatic, marked microcytosis (MCV 68) with a normal RDW (implied by high RBC count for the degree of anemia) and normal iron studies is classic for beta thalassemia minor (trait). The definitive diagnosis is made by hemoglobin electrophoresis, which characteristically shows an elevated level of Hemoglobin A2 (>3.5%). Increased Hemoglobin F is more prominent in beta thalassemia major. Hemoglobin S is characteristic of sickle cell disease. Alpha thalassemia trait would typically have normal hemoglobin electrophoresis results.
- A 31-year-old woman who follows a strict vegan diet presents with fatigue and glossitis. She recently began self-medicating with large doses of folic acid after reading about anemia online. Laboratory data: Hb 7.9 g/dL, MCV 103 fL, leukocytes 3,800/µL, platelets 92,000/µL. Peripheral smear shows oval macrocytes, anisopoikilocytosis, and hypersegmented neutrophils. Serum folate is high, and vitamin B12 level is very low. What is the most likely explanation for the persistent cytopenias despite folate supplementation?
Answer: Accumulation of methylmalonyl-CoA causing defective myelin synthesis and ineffective hematopoiesis
When you encounter a case of megaloblastic anemia with neurological symptoms in a vegan patient, think about the intricate relationship between folate and vitamin B12 metabolism. Both vitamins are essential for DNA synthesis, but B12 has unique additional roles that folate cannot replace.
The correct answer is A. In B12 deficiency, methylmalonyl-CoA accumulates because B12 is required as a cofactor for methylmalonyl-CoA mutase. This accumulation leads to incorporation of abnormal fatty acids into cell membranes, particularly affecting myelin synthesis in the nervous system and causing ineffective hematopoiesis in the bone marrow. While folate can temporarily help with DNA synthesis (explaining why some patients initially improve), it cannot address the methylmalonyl-CoA pathway dysfunction, leading to persistent cytopenias and potential neurological damage.
Option B incorrectly suggests this is iron deficiency, but the high MCV and macrocytic picture clearly indicate megaloblastic anemia, not iron deficiency (which causes microcytosis). Option C presents a common misconception - folate doesn't compete with B12 for absorption since they use different transport mechanisms. Option D misinterprets the pathophysiology; this isn't aplastic anemia but rather ineffective hematopoiesis due to B12-specific metabolic dysfunction.
Remember this key principle: folate can mask the hematological signs of B12 deficiency but cannot prevent the neurological complications or completely correct the ineffective hematopoiesis. Always check B12 levels in megaloblastic anemia, especially in vegans, and never give folate alone without ruling out B12 deficiency first.
- A 68-year-old man with non–valvular atrial fibrillation on warfarin therapy is incidentally found to have Hb 9.4 g/dL and MCV 83 fL. Platelet and leukocyte counts are normal. Reticulocyte index is elevated. Labs: LDH 480 U/L, haptoglobin undetectable. Direct Coombs test is negative. Peripheral smear shows schistocytes. Creatinine is 1.0 mg/dL. INR is 2.3. Which of the following is the most likely cause of his anemia?
Answer: Mechanical destruction of erythrocytes by turbulent flow across aortic valve stenosis
When you encounter hemolytic anemia with schistocytes on peripheral smear, think about causes of intravascular hemolysis. The key laboratory findings here—elevated LDH, undetectable haptoglobin, elevated reticulocyte index, and negative direct Coombs test—all point to non-immune intravascular hemolysis.
The presence of schistocytes (fragmented red blood cells) is the crucial diagnostic clue. These form when red blood cells are mechanically sheared by abnormal blood flow patterns. In this elderly patient, the most likely cause is turbulent flow across a stenotic aortic valve, which creates high shear stress that fragments passing erythrocytes. This condition is known as microangiopathic hemolytic anemia (MAHA).
Looking at the wrong answers: B) Extravascular hemolysis typically occurs in the spleen and wouldn't produce schistocytes or cause undetectable haptoglobin—haptoglobin depletion is characteristic of intravascular hemolysis. C) While warfarin can cause bleeding, the therapeutic INR of 2.3 and normal creatinine make significant occult bleeding unlikely. More importantly, bleeding wouldn't explain the schistocytes or hemolysis markers. D) Cold agglutinin disease would show a positive direct Coombs test and typically causes extravascular hemolysis without schistocytes.
Remember this pattern: schistocytes + intravascular hemolysis markers (low haptoglobin, high LDH) + negative Coombs = mechanical hemolysis. In elderly patients, always consider aortic stenosis as a cause. This combination of findings should immediately make you think of valve disease or other causes of turbulent blood flow.
- A 42-year-old woman with long-standing rheumatoid arthritis presents with progressive fatigue. Laboratory studies show Hb 9.2 g/dL, MCV 78 fL, serum iron 35 µg/dL (60-170), transferrin saturation 10% (20-50), total iron-binding capacity 180 µg/dL (250-400), and ferritin 380 ng/mL (15-150). What is the most appropriate next step in management?
Answer: Treat underlying inflammation with escalation of disease-modifying antirheumatic therapy
When you encounter anemia in patients with chronic inflammatory conditions like rheumatoid arthritis, you need to distinguish between iron deficiency anemia and anemia of chronic disease (ACD). This patient's lab pattern is classic for ACD: low serum iron, low transferrin saturation, but crucially, low total iron-binding capacity (TIBC) and elevated ferritin.
In true iron deficiency, you'd expect high TIBC (>400 µg/dL) as the body tries to capture more iron, and low ferritin (<15 ng/mL). Here, the elevated ferritin (380 ng/mL) indicates adequate iron stores, but the iron is sequestered and unavailable due to chronic inflammation. The inflammatory cytokines, particularly IL-6, increase hepcidin production, which blocks iron release from macrophages and decreases iron absorption.
Choice C is correct because treating the underlying inflammation is the primary intervention for ACD. Better disease control will reduce inflammatory cytokines, decrease hepcidin, and allow stored iron to become available for erythropoiesis.
Choice A is wrong because IV iron won't help when iron stores are already adequate but sequestered. Choice B fails for the same reason - oral iron supplementation is ineffective in ACD and may even worsen inflammation. Choice D (bone marrow biopsy) would be appropriate if you suspected sideroblastic anemia, but the clinical picture doesn't support this.
Study tip: Remember the ferritin level as your key differentiator - low in iron deficiency, high in anemia of chronic disease. When ferritin is elevated in chronic inflammatory conditions, treat the inflammation, not the iron.
- A 67-year-old man treated with chronic omeprazole therapy for gastroesophageal reflux disease presents with paresthesias of both feet and macrocytic anemia. Labs: Hb 10.6 g/dL, MCV 114 fL, leukocytes 4,500/µL, platelets 110,000/µL. Peripheral smear shows hypersegmented neutrophils. Serum methylmalonic acid and homocysteine are both elevated. Which pathophysiologic mechanism most likely explains his cytopenias?
Answer: Autoimmune destruction of gastric parietal cells causing impaired intrinsic factor production
When you encounter a patient with macrocytic anemia, paresthesias, and elevated methylmalonic acid plus homocysteine, you're dealing with vitamin B12 deficiency. The key insight here is recognizing how chronic proton pump inhibitor (PPI) use can lead to this deficiency through an autoimmune mechanism.
Chronic PPI therapy reduces gastric acid production, which over time can trigger autoimmune gastritis. This autoimmune process targets gastric parietal cells, the same cells that produce intrinsic factor essential for B12 absorption in the terminal ileum. Without intrinsic factor, B12 deficiency develops, leading to megaloblastic anemia (high MCV, hypersegmented neutrophils) and neurologic symptoms (paresthesias). The elevated methylmalonic acid and homocysteine confirm B12 deficiency specifically, as these metabolites accumulate when B12-dependent enzymatic reactions are impaired.
Answer A correctly identifies this autoimmune destruction of parietal cells. Answer B is incorrect because folate deficiency would elevate homocysteine but not methylmalonic acid, and folate absorption occurs in the jejunum, which isn't directly affected by PPI-induced gastritis. Answer C mentions copper deficiency, which can cause cytopenias but wouldn't produce the specific lab pattern of elevated methylmalonic acid and homocysteine. Answer D suggests direct myelotoxicity from PPIs, but this doesn't explain the specific B12 deficiency markers or the neurologic symptoms.
Remember: elevated methylmalonic acid + homocysteine = B12 deficiency. In patients on chronic PPIs, think autoimmune gastritis leading to loss of intrinsic factor production.
- Which of the following is the most appropriate next step to determine the etiology of this patient's condition?
Answer: Perform a bone marrow aspiration and biopsy
The patient has pancytopenia, which is a decrease in all three major blood cell lines. The differential diagnosis is broad and includes primary marrow failure (e.g., aplastic anemia, myelodysplastic syndrome), marrow infiltration (e.g., leukemia, lymphoma, metastatic cancer), peripheral destruction (e.g., hypersplenism), and severe nutritional deficiencies. Since the peripheral smear is non-diagnostic (no blasts), the most critical next step is to directly examine the bone marrow. A bone marrow aspiration and biopsy can differentiate between these possibilities by assessing cellularity, morphology, and clonality, thus establishing a definitive diagnosis and guiding further management.
- A 58-year-old man with chronic kidney disease stage 4 is treated with darbepoetin alfa for anemia. After six months, his hemoglobin decreases from 10.2 to 6.9 g/dL. Mean corpuscular volume is unchanged. Reticulocyte count is very low, and leukocyte and platelet counts are normal. Serum iron studies are within normal limits. Which of the following is the most appropriate diagnostic study?
Answer: Serum anti–erythropoietin antibody assay to detect pure red cell aplasia
When you encounter a patient on erythropoiesis-stimulating agents (ESAs) like darbepoetin alfa who develops severe anemia with low reticulocyte count, think about pure red cell aplasia (PRCA) caused by anti-erythropoietin antibodies. This is a well-recognized but rare complication of ESA therapy in CKD patients.
The clinical picture here is classic: a CKD patient on darbepoetin who develops worsening anemia despite treatment, with an inappropriately low reticulocyte count (indicating bone marrow failure to produce red cells) but normal white cells and platelets. This selective red cell production failure, combined with the ESA exposure history, strongly suggests antibody-mediated PRCA.
Option A is correct because serum anti-erythropoietin antibody testing is the specific diagnostic test for ESA-induced PRCA. These antibodies cross-react with both exogenous ESAs and endogenous erythropoietin, completely shutting down red cell production.
Option B (bone marrow aspiration) would show the expected finding of absent erythroid precursors, but it's not the most specific test and doesn't identify the underlying cause. Option C (flow cytometry for PNH) is inappropriate since PNH causes hemolysis with elevated reticulocyte count, not decreased production. Option D (parvovirus B19 PCR) could cause similar findings but is far less likely in this clinical context of ESA therapy.
Remember: ESA-induced PRCA is rare but serious. Always consider it when CKD patients on ESAs develop worsening anemia with low reticulocyte counts, and test for anti-erythropoietin antibodies as the definitive diagnostic study.
- Which of the following is the most appropriate next step to confirm the diagnosis?
Answer: Direct antiglobulin (Coombs) test
The patient's presentation with acute anemia, signs of hemolysis (jaundice, dark urine, high indirect bilirubin, high LDH, high reticulocytes), and spherocytes on smear, in the context of SLE, is highly suggestive of warm autoimmune hemolytic anemia (AIHA). The definitive diagnostic test for AIHA is the direct antiglobulin (Coombs) test, which detects IgG antibodies and/or complement C3 bound to the surface of the patient's red blood cells. The osmotic fragility test is used for hereditary spherocytosis. Hemoglobin electrophoresis is for hemoglobinopathies. A bone marrow biopsy is not indicated as a first step.
- A 46-year-old woman presents with shortness of breath. She has rheumatoid arthritis treated with methotrexate. CBC: Hb 7.2 g/dL, MCV 104 fL, leukocytes 6,000/µL, platelets 340,000/µL. Reticulocyte index is low. Serum folate 2.0 ng/mL (low), vitamin B12 normal. Which medication change will most rapidly improve her anemia?
Answer: Continue methotrexate and co-administer daily leucovorin (folinic acid) supplementation
When you encounter a patient on methotrexate presenting with macrocytic anemia and low folate, you're seeing methotrexate-induced folate deficiency. Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and causing megaloblastic anemia. The key clinical decision is how to correct this while maintaining therapeutic benefit from methotrexate.
The correct approach is C) Continue methotrexate and co-administer daily leucovorin (folinic acid) supplementation. Leucovorin (folinic acid) bypasses methotrexate's enzymatic block because it's already in the reduced form that cells can use directly. Daily dosing rapidly corrects the folate deficiency while allowing continued rheumatoid arthritis treatment.
A is problematic because stopping methotrexate eliminates rheumatoid arthritis control, and regular folic acid still requires the blocked enzyme for activation, making correction slower.
B makes no sense - increasing methotrexate worsens folate depletion, and weekly leucovorin rescue therapy is used for high-dose chemotherapy protocols, not chronic low-dose methotrexate treatment.
D unnecessarily switches effective therapy when the problem is easily correctable. Since B12 levels are normal, B12 injections won't address the folate-deficient megaloblastic anemia.
USMLE Step 2 tip: Remember that methotrexate-induced folate deficiency is common and predictable. The standard prevention/treatment is leucovorin supplementation, which allows continued methotrexate use. Don't fall for options that discontinue effective therapy when simple co-administration of the bypassing agent solves the problem.
